OverviewSuggest Edit

Avidity Biosciences is a biotech company pioneering oligonucleotide-based therapies called antibody oligonucleotide conjugates (AOC). Its therapies are designed to overcome the current limitations of oligonucleotide therapies in order to treat a range of serious diseases. The company utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies (mAbs) and the precision of oligonucleotide therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases.

TypePublic
Founded2013
HQLa Jolla, CA, US
Websiteaviditybiosciences.com

Latest Updates

Employees (est.) (May 2020)38
Job Openings10
Revenue (FY, 2020)$6.8 M
Share Price (Jun 2021)$26.8
Cybersecurity ratingBMore

Key People/Management at Avidity Biosciences

Joseph Baroldi

Joseph Baroldi

Chief Operating Officer
Arthur A. Levin

Arthur A. Levin

Chief Scientific Officer
Michael MacLean

Michael MacLean

Chief Financial Officer
Carsten Boess

Carsten Boess

Director
Sarah Boyce

Sarah Boyce

President & Chief Executive Officer and Director
Elizabeth J. Ackermann

Elizabeth J. Ackermann

Vice President, Clinical Development
Show more

Avidity Biosciences Office Locations

Avidity Biosciences has an office in La Jolla
La Jolla, CA, US (HQ)
10975 N Torrey Pines Rd #150
Show all (1)

Avidity Biosciences Financials and Metrics

Avidity Biosciences Revenue

Avidity Biosciences's revenue was reported to be $6.79 m in FY, 2020
USD

Revenue (FY, 2020)

6.8m

Net income (FY, 2020)

(44.4m)

EBIT (FY, 2020)

(44.3m)

Market capitalization (18-Jun-2021)

1.0b

Closing stock price (18-Jun-2021)

26.8

Cash (31-Dec-2020)

321.5m

EV

687.9m
Avidity Biosciences's current market capitalization is $1 b.
Annual
USDFY, 2020

Revenue

6.8m

General and administrative expense

13.5m

R&D expense

37.6m

Operating expense total

51.1m
Quarterly
USDQ2, 2020Q3, 2020

Revenue

1.5m1.7m

General and administrative expense

2.9m3.8m

R&D expense

9.0m9.5m

Operating expense total

11.9m13.2m
Annual
USDFY, 2020

Cash

321.5m

Prepaid Expenses

3.5m

Current Assets

331.7m

PP&E

1.5m
Quarterly
USDQ2, 2020Q3, 2020

Cash

352.4m341.1m

Prepaid Expenses

1.4m3.2m

Current Assets

353.8m344.3m

PP&E

771.0k1.3m
Annual
USDFY, 2020

Net Income

(44.4m)

Depreciation and Amortization

373.0k

Accounts Payable

5.7m

Cash From Operating Activities

(37.1m)
Quarterly
USDQ2, 2020Q3, 2020

Net Income

(16.6m)(28.1m)

Depreciation and Amortization

157.0k258.0k

Accounts Payable

1.9m4.4m

Cash From Operating Activities

(14.9m)(24.0m)
USDQ2, 2020

EV/EBIT

-62.4 x

EV/CFO

-43.3 x

Revenue/Employee

42.5k

Financial Leverage

1.1 x
Show all financial metrics

Avidity Biosciences Cybersecurity Score

Cybersecurity ratingPremium dataset

B

82/100

SecurityScorecard logo

Avidity Biosciences Online and Social Media Presence

Embed Graph

Avidity Biosciences News and Updates

Avidity Biosciences to Host Virtual Investor and Analyst Event on May 19, 2021

LA JOLLA, Calif., May 3, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it will host a virtual investor and analyst...

Avidity Biosciences Announces 2021 Pipeline Updates and Research Collaboration with MyoKardia

LA JOLLA, Calif., Jan. 8, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced pipeline updates for 2021 and a research...

Avidity Biosciences to Present at the Credit Suisse 29th Annual Virtual Healthcare Conference 2020

LA JOLLA, Calif., Nov. 5, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCsâ„¢), today announced that Sarah Boyce, President and Chief Executive...

Avidity Biosciences jumps 50% in first day of trading

Shares of Avidity Biosciences Inc. soared 50% in their trading debut on the Nasdaq on Friday after pricing at the top of their initial public offering range, a sign of heightened interest from investors. Avidity, a biotech company that the specializes in treatments for muscular disorders, priced it…

Avidity Biosciences prices IPO at $18 a share to raise $259.2 million to fund R&D

Avidity Biosciences Inc. , a biotech the specializes in treatments for muscular disorders, priced its initial public offering at $18 a share late Thursday, the high end of its price range. The company sold 14.4 million shares to raise $259.2 million. The company upsized the deal from an earlier pla…

Avidity Biosciences Announces Pricing of Initial Public Offering

SAN DIEGO, June 11, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq:RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced the pricing of its initial public offering of...
Show more

Avidity Biosciences Blogs

Avidity Biosciences Appoints Carsten Boess to its Board of Directors

SAN DIEGO, April 13, 2020 /PRNewswire/ – Avidity Biosciences (Avidity), a privately-held biopharmaceutical company pioneering Antibody Oligonucleotide Conjugates (AOCs™), announced today the appointment of Carsten Boess to its board of directors.  Mr. Boess, who has nearly thirty years of industry e…

Avidity Biosciences Announces Presentations at Upcoming Investor Conferences

SAN DIEGO, Feb. 24, 2020 /PRNewswire/ — Avidity Biosciences (Avidity), a privately-held biotechnology company pioneering Antibody Oligonucleotide Conjugates (AOCs™), announced today that Sarah Boyce, Avidity’s President and CEO, will present a company overview at two upcoming investor conferences: 9…

Avidity Biosciences Announces Presentation at the 38th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 7, 2020 /PRNewswire/ — Avidity Biosciences (Avidity) announced today that it will present at the 38th Annual J.P. Morgan Healthcare Conference being held January 13-16, 2020 in San Francisco, CA. Sarah Boyce, President and CEO of Avidity, will present an overview of the company’s nov…

Avidity Biosciences Completes $100 Million Series C Financing

La Jolla, Calif., November 13, 2019 (BUSINESS WIRE) – Avidity Biosciences, a biotechnology company pioneering Antibody-Oligonucleotide Conjugates (AOCs™) for the treatment of rare muscle disorders and other serious diseases, announced the completion of a $100 million Series C financing. The financin…

Avidity Biosciences to Present at the 2019 Myotonic Annual Conference

La Jolla, California, September 12, 2019 (PRNEWSWIRE) – Avidity Biosciences, a privately-held biotechnology company pioneering Antibody Oligonucleotide Conjugates (AOCs™), today announced that Arthur A. Levin, Ph.D., Chief Scientific Officer, is scheduled to present at the 2019 Myotonic Annual Confe…

Avidity Biosciences Adds Drug Development Veterans Edward Kaye and Noreen Henig to Board of Directors

La Jolla, California, August 22, 2019 (PR NEWSWIRE) – Avidity Biosciences, a biotechnology company pioneering Antibody-Oligonucleotide Conjugates (AOCs™) focused in rare muscle disorders and other serious diseases, today announced the appointment of Noreen Henig, M.D. and Edward Kaye, M.D., to the c…

Avidity Biosciences Frequently Asked Questions

  • When was Avidity Biosciences founded?

    Avidity Biosciences was founded in 2013.

  • Who are Avidity Biosciences key executives?

    Avidity Biosciences's key executives are Joseph Baroldi, Arthur A. Levin and Michael MacLean.

  • How many employees does Avidity Biosciences have?

    Avidity Biosciences has 38 employees.

  • What is Avidity Biosciences revenue?

    Latest Avidity Biosciences annual revenue is $6.8 m.

  • What is Avidity Biosciences revenue per employee?

    Latest Avidity Biosciences revenue per employee is $178.6 k.

  • Who are Avidity Biosciences competitors?

    Competitors of Avidity Biosciences include Genkyotex, Lupin and Galapagos.

  • Where is Avidity Biosciences headquarters?

    Avidity Biosciences headquarters is located at 10975 N Torrey Pines Rd #150, La Jolla.

  • Where are Avidity Biosciences offices?

    Avidity Biosciences has an office in La Jolla.

  • How many offices does Avidity Biosciences have?

    Avidity Biosciences has 1 office.